Enhancing monoclonal antibodies with natural products: Mechanisms and applications

Monoclonal antibodies (mAbs) have revolutionized therapeutic strategies across a broad spectrum of diseases, yet their efficacy remains constrained by challenges such as suboptimal tumor penetration and insufficient cytotoxicity. This study pioneers an integrative approach, harnessing the untapped potential of plant-derived glycosides and innovative biotechnological advances to redefine mAb efficacy. Specifically, we investigate the novel application of beta-glucan analogs engineered for enhanced immunomodulatory effects, targeting not only malignant cells but also the tumor microenvironment to optimize mAb penetration. Moreover, we introduce a groundbreaking strategy in antibody-drug conjugates (ADCs) by leveraging previously unexploited natural toxins, such as modified saporin variants, which are bioengineered to achieve selective cytotoxicity with minimal off-target effects. This novel ADC formulation is further optimized through the use of nanoencapsulation techniques, ensuring precise delivery and controlled release within the tumor milieu. The research also focuses on hybrid expression systems, scalable mAb production, nanoencapsulation for targeted delivery, and the integration of natural and synthetic techniques for improved antibody therapies. By combining plant-based expression systems with synthetic biology tools, creating a hybrid platform that surpasses traditional plant or mammalian systems in both yield and safety. This approach not only reduces production costs but also introduces a scalable method for the rapid adaptation of mAbs in response to emerging pathogens or tumor mutations. This study opens new avenues by blending natural and synthetic methodologies, ultimately enhancing the therapeutic outcomes of mAbs across various disease states. It underscores the transformative potential of integrating cutting-edge technologies with natural compounds, paving the way for more effective, targeted, and adaptable antibody-based therapies.